Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk fartors, angiographic coronary artery disease, and major adverse events at follow-up

European Heart Journal

Volumn 26, Issue 2, 2005, Pages 137-144

  Brilakis, Emmanouil S ^a,c   McConnell, Joseph P ^a   Lennon, Ryan J ^a   Elesber, Ahmad A ^a   Meyer, Jeffrey G ^a   Berger, Peter B ^b  

^a MAYO CLINIC   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Acute myocardial infarction; C reactive protein; Coronary disease; Lipoprotein associated phospholipase A2

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DEATH; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; GENDER; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; STROKE;

ADULT; AGED; BIOLOGICAL MARKERS; CEREBROVASCULAR ACCIDENT; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHOSPHOLIPASES A; RISK FACTORS;

EID: 14144256273     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi010     Document Type: Article

References (12)

1. Tew DG, Southan C, Rice SQ et al. Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler Thromb Vasc Biol 1996;16:591-599.
2. Caslake MJ, Packard CJ, Suckling KE et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000;150:413-419.
3. Hakkinen T, Luoma JS, Hiltunen MO et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999;19:2909-2917.
4. Packard CJ, O'Reilly DS, Caslake MJ et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-1155.
5. Blake GJ, Dada N, Fox JC et al. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001;38:1302-1306.
6. Killip T. The National Heart, Lung, and Blood Institute Coronary Artery Surgery Study (CASS). Circulation 1981;63(Suppl. 1):1-81.
7. Tselepis AD, Chapman JM. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002;3:57-68.
8. MacPhee CH, Moores KE, Boyd HF et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338:479-487.
9. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002; 39:632-637.
10. Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109:837-842.
11. MacPhee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol 2001;1:121-125.
12. Boyd HF, Fell SC, Hickey DM et al. Potent, orally active inhibitors of lipoprotein-associated phospholipase A(2): 1-(biphenylmethylamidoalkyl)- pyrimidones. Bioorg Med Chem Lett 2002;12:51-55.